| BMYMP |
Bristol-Myers Squibb Co |
92%
|
Reciprocal relationship from BMYMP graph: In April 2026, BMS entered into agreements with Dr. Reddy's Laboratories that allow for (i) an Orencia biosimilar for intravenous administration to be market… |
| BMY |
Bristol-Myers Squibb Company |
90%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from RDY graph: Reciprocal relationship from BMY graph: Reciprocal relationship from RDY graph: Reciprocal relationship from BMY graph:… |
| PAR-PHARMACEUTICAL-INC-SUN-PHARMACEUTICALS-LIMIT |
PAR-PHARMACEUTICAL-INC-SUN-PHARMACEUTICALS-LIMIT |
85%
|
t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number … |
| FBIO |
Fortress Biotech, Inc. |
80%
|
Reciprocal relationship from FBIO graph: Journey holds global rights to Emrosi™ (Minocycline Hydrochloride Modified Release Capsules, 40 mg) pursuant to a license agreement with Dr. Reddy's Laborator… |
| DERM |
Journey Medical Corporation |
72%
|
me 5,217 5,426 5,655 License fees (2) 4,503 3,789 2,113 Rs. 335,933 Rs. 325,535 Rs. 279,164 (1) For the year ended March 31, 2026, consequent to resolution of a shelf stock adjustment claim arising f… |
| DERM |
Journey Medical Corporation |
72%
|
Reciprocal relationship from DERM graph: Reciprocal relationship from RDY graph: me 5,217 5,426 5,655 License fees (2) 4,503 3,789 2,113 Rs. 335,933 Rs. 325,535 Rs. 279,164 (1) For the year ended Mar… |
| IMMP |
Immutep Limited |
72%
|
th rate considered does not exceed that of the relevant business and industry sector. d) The post-tax discount rates and pre-tax discount rates used for the Active Pharmaceutical Operations CGU and t… |
| IMMP |
Immutep Limited |
72%
|
Reciprocal relationship from IMMP graph: Reciprocal relationship from RDY graph: th rate considered does not exceed that of the relevant business and industry sector. d) The post-tax discount rates a… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from RDY graph: ell lung cancer following the results of the futility analysis. As a result, the Company recorded an impairment loss … |
| NVSEF |
Novartis AG |
72%
|
ell lung cancer following the results of the futility analysis. As a result, the Company recorded an impairment loss of Rs. 914 (U.S.$ 10 ) in the consolidated income statements forming part of the G… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from SNYNF … |
| SNYNF |
Sanofi |
72%
|
last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Aghanian has experience spanning originator, consumer health and generic pharmaceuti… |
| XYF |
X Financial |
72%
|
Reciprocal relationship from XYF graph: Reciprocal relationship from RDY graph: last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Agha… |
| XYF |
X Financial |
72%
|
last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Aghanian has experience spanning originator, consumer health and generic pharmaceuti… |
